HUTCHMED (China) LtdNASDAQ:HCM
- LAST PRICE17.9500
- TODAY'S CHANGE (%)-0.7500 (-4.0107%)
- Bid / Lots17.1700/ 1
- Ask / Lots18.5900/ 1
- Open / Previous Close18.1000 / 18.7000
- Day Range
- 52 Week Range
- Volume85,779
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HCM |
|---|---|---|
| 09:32 ET | 2250 | 18.185 |
| 09:33 ET | 902 | 18.01 |
| 09:35 ET | 798 | 17.83 |
| 09:37 ET | 200 | 17.82 |
| 09:39 ET | 1010 | 17.88 |
| 09:44 ET | 300 | 17.76 |
| 09:46 ET | 1400 | 17.73 |
| 09:48 ET | 312 | 17.78 |
| 09:50 ET | 392 | 17.81 |
| 09:51 ET | 5481 | 17.93 |
| 10:02 ET | 100 | 17.93 |
| 10:06 ET | 100 | 17.96 |
| 10:09 ET | 688 | 17.91 |
| 10:20 ET | 100 | 17.9 |
| 10:26 ET | 170 | 17.9113 |
| 10:31 ET | 755 | 17.98 |
| 10:33 ET | 800 | 18.02 |
| 10:40 ET | 200 | 18.055 |
| 10:47 ET | 275 | 18 |
| 10:51 ET | 625 | 17.98 |
| 10:56 ET | 100 | 17.99 |
| 11:03 ET | 300 | 17.955 |
| 11:21 ET | 100 | 17.93 |
| 11:38 ET | 200 | 17.95 |
| 11:43 ET | 500 | 17.92 |
| 11:45 ET | 200 | 17.96 |
| 11:50 ET | 300 | 17.95 |
| 12:15 ET | 1000 | 17.9 |
| 12:30 ET | 100 | 17.8901 |
| 12:37 ET | 300 | 17.95 |
| 12:46 ET | 721 | 17.9 |
| 01:11 ET | 200 | 17.92 |
| 01:26 ET | 100 | 17.92 |
| 01:31 ET | 146 | 17.9101 |
| 01:51 ET | 612 | 17.94 |
| 01:54 ET | 247 | 17.95 |
| 02:02 ET | 100 | 17.97 |
| 02:07 ET | 2143 | 17.97 |
| 02:14 ET | 100 | 17.97 |
| 02:25 ET | 822 | 18 |
| 02:32 ET | 1022 | 17.92 |
| 02:48 ET | 647 | 17.95 |
| 02:52 ET | 500 | 17.89 |
| 03:12 ET | 200 | 17.92 |
| 03:19 ET | 700 | 17.91 |
| 03:21 ET | 100 | 17.91 |
| 03:32 ET | 200 | 17.875 |
| 03:35 ET | 532 | 17.88 |
| 03:42 ET | 300 | 17.92 |
| 03:46 ET | 19714 | 17.82 |
| 03:48 ET | 1451 | 17.88 |
| 03:51 ET | 1100 | 17.95 |
| 03:53 ET | 905 | 17.93 |
| 03:55 ET | 100 | 17.9 |
| 03:57 ET | 827 | 17.91 |
| 04:00 ET | 5416 | 17.95 |
Nov 5, 2024
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress, from 11:00PM ET on Tuesday Nov 05, 2024 by Dow Jones
11:00PM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 31, 2024
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
4:30AM ET on Thursday Oct 31, 2024 by Dow JonesPress Release: HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda, from 4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
4:30AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 16, 2024
HUTCHMED Announces that TAGRISSO(R) plus ORPATHYS(R) demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial, from 12:30AM ET on Wednesday Oct 16, 2024 by Dow Jones
12:30AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HUTCHMED (China) Ltd | 3.1B | -71.9x | --- |
PTC Therapeutics Inc | 3.4B | -7.5x | --- |
Amphastar Pharmaceuticals Inc | 2.3B | 15.4x | --- |
Tilray Brands Inc | 1.3B | -5.4x | --- |
Prestige Consumer Healthcare Inc | 4.0B | 19.6x | --- |
Harmony Biosciences Holdings Inc | 2.1B | 17.1x | --- |
Company Information
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Contact Information
- Headquarters
- 48Th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Dan Eldar
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Weiguo Su
- Chief Financial Officer, Executive Director
- Chig Fung Cheng
- Chief Operating Officer, Executive Vice President
- Karen Atkin
- Executive Vice President and Chief Commercial Officer, China
- Hong Chen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $610.8M |
Shares Outstanding | 174.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-0.25 |
Book Value | $4.19 |
P/E Ratio | -71.9x |
Price/Sales (TTM) | 5.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -19.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
